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Clinical Review
SGLT-2 Inhibitors: A Novel Mechanism
in Targeting Glycemic Control in Type 2
Diabetes Mellitus
Kobi T. Nathan, Nabila Ahmed-Sarwar, Paul Werner

OBJECTIVE: To review the chemistry, pharmacology, pharma

codynamics, pharmacokinetics, clinical efficacy, tolerability,
dosing, drug interactions, and administration of canagliflozin,
dopagliflozin, and empagliflozin, and comparing the benefit
and risk aspects of using these agents in the older adult diabe
tes patient population.
DATA SOURCES, STUDY SELECTION, DATA EXTRACTION,
AND DATA SYNTHESIS: A search of PubMed using the

terms "SGLT-2 inhibitors," "canagliflozin," "dopagliflozin,"
"empagliflozin," "efficacy," and "tolerability" was performed to
find relevant primary literature on each of the sodium/glucose
cotransporter 2 (SGLT-2) inhibitors currently approved for use
in type 2 diabetes. Phase III trials for all agents were included.
All English-language articles from 2010 to 2015 appearing in
these searches were reviewed for relevance to this paper. In
addition, related articles suggested in the PubMed search were .
also reviewed. The SGLT-2 inhibitors have shown a reduction
in hemoglobin Ale values and fasting plasma glucose levels
with a low incidence of hypoglycemia. The incidence of mycotic
infections is increased in patients taking an SGLT-2 inhibitor.
CONCLUSION: SGLT-2 inhibitors may be a viable treatment

option for patients not controlled on other oral agents. The risk
of hypoglycemia is small. However, the clinical efficacy and
tolerability of these agents has not been fully elucidated in
older and frail patients.
KEY WORDS: Anti-hyperglycemic agents, Canagliflozin,

Dopagliflozin, Empagliflozin, Hypoglycemia, SGLT-2 inhibitors.
Type 2 diabetes mellitus.
ABBREVIATIONS: ADA = American Diabetes Association, ADC =

Area under the curve. Cl = Confidence interval, CYP = Cytochrome
P450, DPP-4 = Dipeptidyl peptidase-4, eGFR = Estimated glomeru
lar filtration rate, FAERS = Federal Drug Administration Adverse
Event Reporting System, FDA= Food and Drug Administration,
FPG = Fasting plasma glucose, HbAlc = Hemoglobin Ale, SGLT-2
= Sodium/glucose cotransporter 2, T2DM = Type 2 diabetes
mellitus, UGT = UDP-glucuronosyltransferase, UTI = Urinary tract
infection, Vj = Volume of distribution.

Introduction
The long-term glycotoxic effects of persistent
hyperglycemia in type 2 diabetes (T2DM) is well-known
and documented. Treating hyperglycemia can be an
arduous and complicated process for both the provider
and the patient. A myriad of oral anti-hyperglycemic
agents, in addition to insulin, are available to return
patients to normoglycemia. The majority of these agents
(metformin, sulfonylureas, nonsulfonylurea secretagogues,
glucagonlike peptide-1 analog, and dipeptidyl peptidase-4
[DPP-4] inhibitors) are insulin-dependent.' Their efficacy
diminishes over time as pancreatic islet (3-cell function
declines over the natural progression of the disease.'’^
In addition, use of these agents has its limitations,
such as increased risk of hypoglycemia and weight
gain with insulin and sulfonylureas.^-^ Treating older
adults with T2DM poses significant pharmacologic
hurdles and challenges. Complex pharmacodynamic
and pharmacokinetic variables come into play, such
as multiple comorbidities, drug-disease interactions,
drug-drug interactions, polypharmacy, and altered
pharmacokinetics as a result of changes in metabolic
function, adipose, and lean tissue composition.
A novel class of oral anti-hyperglycemic agents, the
SGLT-2 (sodium/glucose cotransportor-2) inhibitors
may hold promise in managing older adults with T2DM,
especially when used as an adjunct to established oral
agents. SGLT-2 inhibitors have an insulin-independent
mechanism of action, which differentiates them from the
other oral anti-hyperglycemic agents. The blood glucose
lowering efficacy of the SGLT-2 inhibitors in T2DM has
been clinically demonstrated in prospective randomized
clinical trials.'-’ * This effect is seen when the SGLT-2
inhibitors are administered as monotherapy or as adjunct
agents with other glucose-lowering medications." Rapid
de-escalations in both basal and postprandial blood
glucose levels are seen, with decreases of hemoglobin Ale
(HbAlc) averaging 0.6% to 1.2%, with the potential to
decrease up to 3% in patients with severely uncontrolled
diabetes.’ '" There are currently three agents in the SGLT2 inhibitor drug class: canagliflozin, dapagliflozin, and
empagliflozin." '’ Several more agents that are currently in
development are listed in Table 1.'’ “
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Table 1. SGLT-2 Inhibitors in Development
Ar’isil ' '

Agent

Development Phase*

i

Ertugliflozin

Phase III

’

Ipragliflozin

Phase III

Luseogliflozin

Phase III

Remogliflozin

Phase lib

’

Tofogliflozin

Phase III

I

Abbreviation: SGLT-2 = Sodium/glucose cotransporter 2.

I
I

• Phase III = Confirms effectiveness, monitors side effects, identifies
indications, and identifies safety parameters

i

•

;

Source: References 16-20.

Phase Mb = Establishes efficacy and further evaluates safety

Source: Reference 12.

Chemistry
The empirical formula is
C24H25F05S*1/2H20, with a molecular weight of 453.53
(Figure 1).'^ The agent is available in a film-coated tablet
for oral administration with either 102 or 306 mg of the
active drug, equating to 100 and 300 mg of anhydrous
canagliflozin, respectively. Canagliflozin is practically
insoluble in aqueous media from pH 1.1 to 12.9." '^
Dapagliflozin: The empirical formula is
C2iH25C106'^C3H802*H20, with a molecular weight
of 502.98 (Figure 2).'^ It is available in a film-coated
tablet for oral administration with either 5 or 10 mg
of the active drug, dapagliflozin propanediol.'^ ''*
Empagliflozin: The empirical formula is C21H25CIO6,
with a molecular weight of 450.91 (Figure 3).^' It is
available in a film-coated tablet for oral administration
with either 10 or 25 mg of the active drug base.'^'^'
Canagliflozin:

Clinical Pharmacology
SGLT-2 is a protein transporter responsible for
approximately 90% of glucose reabsorption at the
proximal renal tubule. Under normal physiological
conditions, the Na-t/K-i- ATPase pump, located
basolaterally within the renal tubules, uses adenosine
triphosphate (ATP) to shuttle three sodium ions to
the blood while bringing two potassium ions into the
intracellular space. This mechanism decreases the
sodium content inside the cell and drives the SGLT2 pump to bring sodium and glucose into the cell. As
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Figure 1. Structural Formula of
Canagliflozin

Figure 2. Structural Formula of
Dapagliflozin

Source: Reference 14.

Figure 3. Structural Formula of
Empagliflozin

Source: Reference 21.
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this pump transports glucose into the cell against its
gradient, its action is considered to be secondary active
transport. The pump cotransports sodium and glucose
at 1:1 stoichiometry from the lumen to the intracellular
space, after which time GLUT-2 brings the reabsorbed
glucose from the intracellular space to the peritubular
capillaries, thereby increasing plasma glucose levels.’’" '^-^'
SGLT-2 has a high capacity, but low affinity for glucose.
SGLT-2 inhibitors bind to SGLT-2, preventing them
from exerting their action of glucose reabsorption. The
result is a greater amount of glucose remaining in the
urine and subsequently excreted from the body. SGLT2 is responsible for approximately 90% of total glucose
reabsorption, and it is estimated that the effect of the
SGLT-2 inhibitors account for a decrease in glucose
reabsorption of about

Pharmacokinetics
The pharmacokinetic profiles for each of the three SGLT-2
inhibitors are detailed in Table
Clinical Efficacy
Several trials have evaluated the clinical efficacy and
tolerability of the three current SGLT-2 inhibitors
approved by the Food and Drug Administration (FDA)
for the treatment of T2DM. Studies have evaluated
this class of medication in comparison to lifestyle
modifications and various other oral anti-hyperglycemic
agents, including sulfonylureas, metformin, and DPP4 inhibitors.This class of medications is not
approved as an add-on therapy to insulin. Overall, each
individual agent has shown a reduction in HbAlc values
and fasting plasma glucose levels with a low incidence of
hypoglycemia.^’^'*

Table 2. Pharmacokinetics of SGLT-2 Inhibitors

Onset of action

Conoglifiozin flnvokonoj^^ Jlapogliflozin (Forxigo)

Empogliflozlp (Jordionce)

Within 24 hours

Within 24 hours

Peak plasma: within 1.5 h

24 hours

24 hours

(dose-dependent)
Duration of action
Absorption

Distribution

postdose

24 hours
Not affected by food;

High-fat meal decreases

Lower absorption with high-

taking before first meal

peak plasma concentration

fat and high-calorie meal;

! may decrease postprandial

by up to 50%

AUC 4-16%, but not clinically

: hyperglycemia
^ Vd:119 L

Vj: 118 L

Vj: 73,8L

significant

Protein binding

99% mainly to albumin

91%

86.2%

Metabolism

O-glucuronidotion by

UGT 1A9 to 1 inactive

Glucuronidation by

UGT1A9&UGT2B4to2

metabolite (Dopagliflozin

UGT28T, UGT1A2, UGT1A3,

inactive metabolites; minor

3-O-glucuronide), minor CYP

UGHT1A8, UGT1A9

- 65%

78%

N/A

100 mg: 10.6 hours

12.9 hours

12.4 hours

CYP3A4 oxidation
Bioovoilobility
Half-life elimination

300 mg: 13.1 hours
Time to peak

1-2 hours

2 hours

1.5 hours

Excretion

Feces (51.7%)

Urine (75%)

Urine (54.4%)

Urine (- 33%)

Feces (21%)

Feces (41.2%)

Abbreviations; AUC = Area under the curve, CYP = Cytochrome P450, SGLT-2 inhibitors = Sodium/glucose cotransporter 2,

UGT = UDP-glucuronosyltransferase, Vj = Volume of distribution.
Source: References 11-15, 21,
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Canagliflozin
Patients with an average HbAlc of 8% who were
randomized to canagliflozin 100 mg daily, 300 mg daily,
or diet and exercise/placebo; canagliflozin 300 mg
once daily produced clinically significant reduction in
HbAlc with absolute reduction of 1.03% at 26 weeks. In
comparison, the 100 mg daily dose achieved an absolute
HbAlc reduction of 0.77% at 26 weeks. Additionally,
the reduction in fasting plasma glucose levels of 27 mg/
dL and up to 34 mg/dL in the canagliflozin 100 mg daily
and 300 mg daily groups, respectively, was observed.
The authors concluded that both the 100 mg and 300
mg dosing regimens provided clinical and statistically
significant improvements in glycemic control. While
acknowledging the ability to improve glycemic targets,
the baseline average fasting plasma glucose levels ranged
from 166 to 172 mg/dL, and even at doses of 300 mg daily,
patients were unable to reach goal fasting blood glucose
levels between 80 and 130 mg/dL as recommended by
the American Diabetes Association.Acknowledging
that goals should be individualized for each patient, the
reduction observed with canagliflozin may be clinically
significant in certain patient populations. Clinical trials
including patients with average baseline HbAlc values
ranging from 7.8% to 7.9% determined that canagliflozin
as an add-on therapy to metformin was not inferior in
comparison to glimepiride plus metformin or sitagliptin
plus metformin in reducing HbAlc and fasting plasma
glucose (PPG) values. At 52 weeks, canagliflozin 100
mg daily plus metformin did not produce a clinically
significant reduction in HbAlc values (0.01%; 95%
confidence interval [Cl] -0.11%-0.09%). Canagliflozin 300
mg daily plus metformin resulted in an absolute HbAlc
reduction of approximately 0.12% (95% Cl -0.22% to
-0.02%) compared with patients randomized to either
glimepiride plus metformin or sitagliptin plus metformin.
The results of these studies indicate the combination of
canagliflozin and metformin does not provide greater
benefits in glycemic control compared with previously
available medication classes.^'^
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Dapagliflozin
Similar efficacy is demonstrated in noninferiority trials
evaluating dapagliflozin.^^'^‘‘ The safety and efficacy
of dapagliflozin has been evaluated in comparison to
metformin, as an add-on to metformin or sulfonylureas,
and as add-on therapy to metformin and sitagliptin.
Patients with T2DM inadequately controlled on
metformin were randomized to receive dapagliflozin 5
mg and 10 mg in addition to continuing their high-dose
metformin therapy.^^ A reduction in HbAlc of 0.7% in
patients receiving 5 mg and 0.84% in patients receiving 10
mg from an average baseline HbAlc of 8.1% was observed
at 24 weeks, in comparison to an HbAlc reduction of 0.3%
seen in patients continuing metformin monotherapy. The
addition of high-dose dapagliflozin has demonstrated
the overall ability to provide an additional 0.54% HbAlc
decrease in comparison to metformin alone. In a small
subset of patients with baseline HbAlc values > 9%,
an overall reduction of 0.84% in HbAlc was observed
at 24 weeks when compared with patients receiving
metformin monotherapy. The absolute difference in PPG
in patients receiving the combination of dapagliflozin and
metformin was no greater than 17 mg/dL when compared
with metformin monotherapy. The authors of this study
concluded at 24 weeks that the addition of dapagliflozin to
patients inadequately controlled on metformin resulted in
a significant reduction in HbAlc and PPG. Acknowledging
that a statistically significant improvement is observed,
the limited HbAlc reduction achieved may have an
inadequate impact on reducing long-term complications
of diabetes. The potential for a greater HbAlc reduction
observed in patients with higher baseline HbAlc values
may provide a greater clinical impact.
Additionally, dapagliflozin has been studied as an
add-on therapy for patients inadequately controlled on
glipizide or glimepiride.^^'^"* Patients with an average
baseline HbAlc of 7.8% did not achieve a statistically or
clinically relevant difference in HbAlc reduction when
comparing dapagliflozin 10 mg with glipizide (-0.5% vs.
-0.52%; P = NS, respectively).^"* In patients with a baseline
HbAlc of approximately 8.1%, the difference in HbAlc
reduction was observed to be no greater than 0.27% when
comparing patients receiving dapagliflozin in addition to
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glimepiride versus glimepiride monotherapy. Although a
greater HbAlc reduction was seen in patients receiving
the combination, approximately 30% of these patients
required additional therapies as a result of poor control,
indicating that the additional HbAlc reduction cannot be
contributed to the addition of dapagliflozin alone.^’
In contrast to the findings of canagliflozin, dapagliflozin
in addition to sitagliptin + metformin compared with
sitagliptin ± metformin demonstrated an additional
reduction of 0.4% from baseline in patients with baseline
HbAlc of 7.9% at 24 weeks. Dapagliflozin did demonstrate
that patients with baseline HbAlc > 8% achieved a
greater HbAlc reduction from baseline of 0.8% and
absolute reduction in fasting plasma glucose of -27.9 mg/
dL compared with placebo. The authors concluded the
addition of dapagliflozin in patients inadequately controlled
on sitagliptin with or without metformin therapy provides
additional clinical benefits.* Although the clinical benefit
of an overall reduction of 0.4% is questionable, the greater
Ale reduction observed in patients with higher baseline
HbAlc levels may provide a greater clinical impact in
prevention of long-term complications of hyperglycemia.
Empagliflozin
In contrast, the most recently FDA-approved SGLT-2
inhibitor, empagliflozin, has been largely studied as an
add-on therapy to metformin, being compared with the
combination of metformin with either a sulfonylurea or
DPP-4 inhibitor.“ When compared with placebo plus
metformin as an add-on to metformin, empagliflozin 10
mg daily and 25 mg daily plus metformin produced similar
absolute HbAlc reductions, 0.57% and 0.64%, respectively,
at 24 weeks."* Similarly, when both strengths of empagliflozin
plus metformin were compared with sitagliptin plus
metformin, the HbAlc reductions achieved were
consistent with those found when compared with placebo
plus metformin and remained consistent at 78 weeks.* A
comparison of empagliflozin 25 mg daily plus metformin
and glimepiride plus metformin found no difference in
reducing HbAlc levels between the two treatment groups.*^*
The overall reductions in FPG seen with empagliflozin in
clinical trials, regardless of comparator, were similar to those
in trials evaluating canagliflozin.
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In a subgroup analysis of patients with baseline HbAlc
> 10% (n = 69), a significantly greater absolute HbAlc
reduction of 3.23% and FPG reduction of 38 mg/dL
compared with placebo was achieved. This indicates the
potential for empagliflozin to provide a greater impact
on improving glycemic control in patients with higher
baseline HbAlc levels.^ A limitation of these findings
is the study protocol allowed for the use of rescue
medication use in patients with elevated fasting blood
glucose levels or patients with HbAlc > 8.5% at scheduled
follow-ups during the 24-week period. The empagliflozin
trials concluded a significant improvement in glycemic
control compared with other oral anti-hyperglycemic
agents."*'*'^* The subgroup analysis of patients with
HbAlc > 10% provides compelling data to hypothesize
hyperglycemia-dependent clinical efficacy.
Tolerability
SGLT-2 inhibitors have demonstrated to be well tolerated
in clinical trials, resulting in a low study-withdrawal rate.*'
5,8,22 qijg trials consistently reported no significant changes
in renal function and serum electrolytes in patients
randomized to either SGLT-1 inhibitors or comparator
oral anti-hyperglycemic agents. This is in contrast to the
postmarketing reports and subsequent FDA warning
regarding the increase in risk of ketoacidosis associated
with this class of medication.*®
In early 2016, FDA added new warnings and precautions
to labels of all SGLT-2 inhibitors following a review of the
FDA Adverse Event Reporting System (FAERS) database
from March 2013 to May 2015. Seventy-three cases of
ketoacidosis in patients with type 1 and type 2 diabetes
were reported. Presentation was serious enough to warrant
hospitalization or treatment in the emergency department.
In several instances, ketoacidosis was not identified, and
treatment was delayed because of patients presenting in a
euglycemic state. Additionally, 19 cases of life-threatening
urosepsis and pylenonephritis were added to the FAERS
database from March 2013 to October 2014. All patients
required hospitalization, with some requiring admission to
an intensive care unit or dialysis to treat acute kidney injury.*®
The rates of hypoglycemia for patients randomized to
receive this class of medication was not significantly different
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Table 3. Reports of Adverse Drug Reactions
Percentage of patients reporting adverse drug reaction for each agent

Adverse Drug

Dapagliflozin +

Empagliflozin

Canagliflozin -i-

Reaction

Metformin

-1- Metformin

Metformin

Hypoglycemia

2%-4%

1.8%-2.4%

2%-6%

Sitagliptin +

Glimepiride +

Metformin

Metformin

0.5%-3.6%

3.6%-5%

N/A

Metformin

(0.9%-1.8%
monotherapy)
Osmotic

N/A

N/A

3%-5%

N/A

N/A

< 1%

4%-8%

9%-12.7%

6%-12%

4.9%-8%

12.5%

5%

3%-11.1%

0%-5%

0%

1.6%

diuresis
UTIs

(3.8%-6.4%
monotherapy)
Genital
infections

8%-13%

3%-3.6%
(3.7%-5.8%
monotherapy)

Abbreviations: N/A = Not reported in study, UTI = Urinary tract infection.
Source: References 3-5, 8, 9.

in comparison to metformin, sitagliptin, and sulfonylureas.^'^
The reported increase in urinary glucose excretion of
approximately 20 g in patients receiving an SGLT-2 inhibitor
in comparison to metformin.^ Adverse reactions resulting
from an increase in glucose in the renal and genital urinary
tract can be expected. Adverse drug reactions such as
occurrence of urinary tract infections (UTIs), genital
infections, and osmotic diuresis for each of the SGLT-2
inhibitors are listed in Table 3. No significant difference in
the occurrence of osmotic diuresis was observed in patients
randomized to receive SGLT-2 inhibitors.^ ®
The occurrence of UTIs for all three agents—dapagliflozin, empagliflozin, and canagliflozin—was not different
when compared with metformin or glimepiride after 24
weeks of therapy.’ Patients receiving empagliflozin were
followed for an extended duration of 78 weeks; the rate
of UTIs were lower in patients receiving empagliflozin
monotherapy in comparison to those on combination
empagliflozin and metformin (3.8%-6.4% vs. 12.7%). No
significant difference in the rate of UTIs was observed
in patients receiving empagliflozin and metformin in
comparison to those receiving sitagliptin and metformin
(12.7% vs. 12.5%, respectively).®

256

Unlike UTIs, the reports of genital infections
described as mild to moderate were significantly higher
in patients receiving SGLT-2 inhibitors in comparison
to metformin, sitagliptin, and sulfonylureas.®‘® “ In
comparison to canagliflozin and dapagliflozin, the reports
of genital infections occurred less frequently in patients
receiving empagliflozin, with a higher incidence in female
than male patients.
SGLT-2 inhibitors were associated with reductions in
systolic blood pressure; reductions were slightly higher
when SGLT-2 inhibitors were used in combination with
metformin therapy.'*'^^'^®'^® The greatest reduction in systolic
blood pressure was reported to be 5.4 mmHg from baseline
in patients randomized to receive canagliflozin 300 mg
daily.“ Reports of orthostatic hypotension were reported
in < 1% of patients randomized to canagliflozin as an add
on to metformin in comparison to no reports in patients
receiving glimepiride and metformin.® At 48 weeks, no
difference was found between patients randomized to
dapagliflozin as an add-on therapy to sitagliptin with or
without metformin in the occurrence of hypotension,
dehydration, and hypovolemia.®
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Drug Interactions
Drug interactions with SGLT-2 inhibitors are relatively
limited in comparison to other oral anti-hyperglycemic
agents.The potential to enhance the hypoglycemic
effects of SGLT-2 inhibitors is possible when combined
with insulin and insulin secretagogues.^' Initiating lower
doses of the SGLT-2 inhibitors in combination with
reduction in dose of prandial insulin doses and short
acting sulfonylureas can reduce the risk of hypoglycemic
events. Additionally, the potential for osmotic diuresis
leading to volume depletion, resulting from increases
in urine volume and polyuria, is higher in patients
concurrently receiving SGLT-2 inhibitors and diuretics.^*
Dose reductions of loop diuretics (i.e., furosemide and
torsemide) should be considered when concurrently
used with SGLT-2 inhibitors. Drug interactions specific
to canagliflozin include UDP-glucuronosyltransferase
(UGT) enzyme inducers and digoxin. Concurrent use
of nonselective UGT enzyme inducers (i.e., rifampin,
phenytoin, phenobarbital, ritonavir) significantly reduces
the area under the curve (AUC) of canagliflozin. Patients
on concurrent UGT enzyme-inducer therapy are likely to
require canagliflozin 300 mg daily to achieve therapeutic
drug levels.'^ Additionally, canagliflozin has the potential
to increase the AUC and mean peak drug concentration
of digoxin.'^ Monitoring digoxin levels in patients
receiving concurrent digoxin and canagliflozin therapy

after initiation or adjustments in canagliflozin dosing can
be utilized to monitor for digoxin toxicity. Canagliflozin
did not inhibit 1A2, 2A6, 2C19, or 2E1 isoenzymes and
weakly inhibited 2B6, 2C8, 2C9, and 3A4.

Dosing and Administration
The currently available dosage formulations for
products containing SGLT-2 inhibitors are available in
Table 4.>2,14.21,29-31
medication is approved for
use in patients with T2DM and has primarily been studied
in individuals older than 18 years of age. No specific
hepatic dosage adjustments are required in patients with
hepatic impairment. The efficacy of this medication
class is significantly dependent on renal clearance; the
recommendations are based on estimated glomerular
filtration rate (eGFR) for each agent and vary slightly.
All three agents are determined to be safe and efficacious
in patients with eGFR > 60 mL/min.‘^ '‘'’^''^^^' The use
of dapagliflozin is not recommended in patients with
eGFR < 60 mL/min.''* Canagliflozin and empagliflozin
are not recommended in patients with an eGFR < 45
mL/min.‘^'^' The dose of canagliflozin should not exceed
100 mg daily in patients with eGFR between 45-59 mL/
min.‘^ To maximize efficacy it is ideal to instruct patients
to administer these medications once daily prior to their
morning meal. Appropriate adjustments to timing of the
medication should be made for patients to align with

Table 4. Commercially Available Formulation of SGLT-2 Inhibitors
Product

4|-

Avallgble strengths

Frequency of administration

Farxiga (dapagliflozin)

5 mg and 10 mg tablets

Every morning

Invokana (canagliflozin)

100 mg and 300 mg tablets

Every morning

Jardiance (empagliflozin)

10 mg and 25 mg tablets

Every morning

Combination products

Xigduo XR (dapagliflozin/metformin)

5/500 mg, 5/1,000 mg, 10/500 mg,

1

Every morning

1

Every morning

10/5,000 mg tablets
Invokamet (canagliflozin/metformin)

50/500 mg, 50/1,000 mg, 150/500
mg, 150/5,000 mg tablets

Glyxambi (empagliflozin/linagliptin)

10/5 mg, 25/5 mg tablets

j Every morning

Abbreviation: SGLT-2 = Sodium/glucose cotransporter 2.
Source: References 12, 14, 21, 33-35.
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timings when dietary intake is consistent with a longer
duration of time (i.e., night-shift workers).

Table 5. Approximate Cost of
SGLT-2 Inhibitors

Pharmacoeconomics
Currently, there are no pharmacoeconomic studies
comparing the cost-effectiveness of the SGLT-2 inhibitors
as a drug class. The average wholesale price pricing for
each agent in this drug class is outlined in Table

Agent

.

Wfiol Dose*

„

Canagliflozin (Invokana)

100 mg once daily ($340)

Dapagliflozin (Farxigo)

5 mg once doily ($340)

Empogliflozin (Jordionce)

10 mg once doily ($340)

* Approximate cost for 30-day supply.

Abbreviation: SGLT-2 = Sodium/glucose cotransporter 2.
Source; Reference 32.

Discussion and Recommendations
Overall, SGLT-2 inhibitors have been shown to reduce
HbAlc values and FPG levels with a low incidence of
hypoglycemia. The safety and efficacy of each agent in
this novel drug class has been evaluated against the other
established oral antidiabetic agents, such as metformin,
the sulfonylureas, and the DPP-4 inhibitors. However, for
patients with HbAlc 7.8%-8.1%, the clinical significance
of these reductions may prove to be questionable in the
larger scenario of effective glycemic control in patients
with type 2 diabetes. Notably, the modest reduction in
HbAlc percentage for each agent as discussed in the
various studies fail to make a clinically relevant reduction
in HbAlc values, limiting their benefits to patients within
1% from achieving their goal HbAlc. However, the SGLT2 inhibitor class has demonstrated, but not established,
the possibility of providing a greater HbAlc reduction
in patients with significantly elevated HbAlc values
(> 10.0%), suggesting a potential to provide clinically
significant reductions in HbAlc values in this subset
of diabetic patients."* For these individuals, the SGLT-2
inhibitors may provide a viable alternative to insulin
therapy. Conversely, cost may prove to be prohibitive in its
use as an adjunct treatment option; the cost of insulin is
significantly less than this novel class of agents. Providers
and patients will have to weigh the benefits versus risks of
insulin therapy over SGLT-2 inhibitor therapy.
Clinical studies suggest that the SGLT-2 inhibitors
are well-tolerated by patients, with the most common
events being osmotic diuresis and mycotic infections. The
incidence of these adverse events was low in the trials;
however, the average age of patients included in currently
available SGLT-2 inhibitor studies ranged from 51.0 to
60.8 years. The limited number of patients older than 70
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Table 6. Education Points for Patients on
SGLT-2 Inhibitor Therapy
1 Adverse Drug

Signs and Symptoms Requiring 1

I Reaction

Referral to Clinician

Mycotic infections

[I.

• Vaginal itching or burning
• Abnormal vaginal discharge
• Urinary frequency

Urinary tract infections

• Urinary frequency
• Flank pain
• Fever
• Dysuria
• Urinary frequency

Hypovolemia

• Orthostasis
• Dizziness
• Elevated skin turgor
• Dry mucus membranes

Renal dysfunction

• Dark urine
• Weakness/fatigue

i

• Urinary frequency
• Hypotension
Ketoacidosis

• Mental confusion
• Extreme fatigue
• Nausea and vomiting
• Abdominal pain
• Hyperventilation

Source: References 12, 14, 21.
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years of age poses a challenge in extrapolating the safety
endpoints in geriatric patients.* Consequently, the safety
and efficacy of these agents has not been ascertained in the
older and frail patient population with multiple comorbid
conditions. Older patients, because of natural biophysical
changes, are more prone to the deleterious effects of
dehydration and UTIs. Use of the SGLT-2 inhibitors, with
resultant osmotic diuresis, decreased intravascular volume,
and possible electrolyte derailment, may lead to potentially
harmful consequences in older adults. In addition, older
patients, especially women and those with diabetes, are
at increased risk for genital infections. An increase in
rates of such events has been reported in all studies of the
SGLT-2 inhibitors.*'^ * Older adults manifest hypoglycemia
differently than the general younger population, and are
also more prone to its effects. The consequences of these
adverse drug reactions have the potential to cause harm
to elderly patients. Pharmacists should ensure patients are
adequately educated on signs and symptoms that indicate
the need for provider intervention, as listed in Table 6.
While the studies show a low incidence of hypoglycemic
events, use of these agents may not be appropriate in
certain patients, and should warrant close scrutiny and
vigilance by medical providers and caretakers.

Conclusion
The SGLT-2 inhibitors are a novel class of oral antihyperglycemic agents that have been shown to decrease
HbAlc values in patients with T2DM. These drugs
may be used as adjunct treatment with other oral antihyperglycemic agents belonging to the biguanide,
sulfonylurea, and DPP-4 inhibitor drug classes. Studies
suggest HbAlc decreases may be more clinically relevant
in patients with higher HbAlc values. The safety and
tolerability of SGLT-2 inhibitors has not been elucidated
in older patients. Although reports of SGLT-2 inhibitors
negatively affecting renal clearance are limited, and no
significant differences in the occurrence of hypotension
and volume-related complications were observed in
clinical trials, elderly patients may be at greater risk for
developing these adverse effects. Frequent monitoring of
renal function, volume status, and blood pressure may be
required to ensure safe medication use. Caution, clinical
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prudence, and careful weighing of benefits versus risks is
recommended when use of these agents is contemplated
in these patients.
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